Research Article

Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer

Mingfu Tong,¹ Wenquan Lu,² Hao Liu,³ Jian Wu,³ Mingzuo Jiang,³
Xin Wang,³ Jianyu Hao ¹, and Daiming Fan ^{1,3}

¹Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

²Department of Gastroenterology, First Affiliated Hospital, Zhengzhou University, Henan, Zhengzhou 450000, China

³State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China

Correspondence should be addressed to Jianyu Hao; haojianyu@ccmu.edu.cn and Daiming Fan; fandaim@fmmu.edu.cn

Received 18 April 2019; Accepted 25 June 2019; Published 17 July 2019

Guest Editor: Xiao-Jie Lu

Copyright © 2019 Mingfu Tong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Metallothioneins (MTs) family comprises many isoforms, most of which are frequently dysregulated in a wide range of cancers. However, the expression pattern and exact role of each distinct MT family isoform which contributes to tumorigenesis, progression, and drug resistance of gastric cancer (GC) are still unclear. **Methods.** Publicly available databases including Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, SurvExpress, MethHC, cBioportal, and GeneMANIA were accessed to perform an integrated bioinformatic analysis and try to detect fundamental relationships between each MT family member and GC. **Results.** Bioinformatic data indicated that the mRNA expression of all MT family members was almost lowly expressed in GC compared with normal gastric tissue ($P < 0.05$), and patients with reduced mRNA expression of each individual MT member had inconsistent prognostic value (OS, FP, PPS), which depended on the individual isoform of MT. A negative correlation between the methylation in promoter region of majority of MT members and their mRNA expression was detected from MethHC database ($p < 0.001$). Data downloaded from TCGA revealed that MTs were rarely mutated in GC patients and MT2A was frequently regulated by other three genes (FOS, JUN, SP1) in GC patients. **Conclusion.** MTs were nearly downregulated, and distinct type of MT harbored different prognostic role in GC patients. Methylation in gene promoter region of MTs partially contributed to their reduced expression in GC. Our comprehensive analyses from multiple independent databases may further lead researches to explore MT-targeting reagents or potential diagnostic and prognostic markers for GC patients.

1. Introduction

Epidemiological data from the WHO suggested that gastric cancer (GC) is the fifth most common malignant tumor and the third leading cause of cancer related death throughout the world, with 1,033,701 new cases and 782,685 deaths in 2018 [1]. Despite a decline rate in incidence and important advances in understanding of the epidemiology, pathology, molecular mechanisms, and treatment options made, the disease was still among the poorest of all solid-organ tumors, predominately due to the frequent presence of advanced stage of the cancer once at first diagnosis [2]. In order to improve the survival of advanced GC patients, based

on palliative surgery and chemotherapy, targeted therapy had been introduced and was expected to be an important supplementary treatment for gastric cancer [3]. Furthermore, exploring new highly specific and sensitive biomarkers and new molecular targets can not only improve the prognosis of GC patients, but also help to elucidate the molecular mechanism of GC.

Metallothioneins (MTs) are a group of high conserved, low molecular metal-binding proteins with a high content of cysteinyl residues that had been found in bacteria, plants, invertebrates, and vertebrates [4]. In mammals, MTs are clustered on chromosome 16 and encode four protein isoforms whose amino acids varying from 61 to 68, labelled

by numbers: MT1, MT2, MT3, and MT4 [5]. Despite the physical and chemical similarity of MT isoforms, their roles and presence in tissues vary significantly. MT1 comprises eight functional paralogs, named MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, and MTX, present almost in all types of soft tissue [6]. MT2 gene only encodes one isoform, called MT2A, also existing prevalently like MT1. MT3 and MT4 are both encoded by one single gene, whereas they are expressed respectively in brain tissues and epithelial cells [6]. Although abundant researches appeared, the proper functions of MTs are still illusive. Nevertheless, MTs had been implicated in a wide range of properties like homeostasis maintenance, detoxification, DNA damage protection, redox pool maintenance, inflammation, and cancer regulation [7].

It is not surprising that MTs are involved in many cancer processes, but the expression and role of MTs is not uniform in kinds of malignancy [8–11]. Discordant results regarding the expression of MT and its association with clinicopathological parameters and prognosis were observed in gastric cancer tissue compared to normal tissue in different studies [12–20]. In addition, the change of MT1/2 protein expression differs from the change of single MT isoform in malignant melanoma tumor, like MT1E and MT1G [21–23]. As such, it is urgent to systematically investigate the expression and role of each isoform of MTs in gastric cancer. In the present study, we accessed into some available databases, like Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, SurvExpress, MethHC, cBioportal, and GeneMANIA to systematically evaluate MT family isoforms in gastric cancer, which may be able to pave the way to well-understand the expression and role of MTs in gastric cancer.

2. Materials and Methods

All datasets obtained from various public databases were analyzed to predict MTs mRNA expression levels, prognostic values, methylation and mutation of metallothionein in tumor tissue compared to normal gastric mucosae.

2.1. Comparison of MTs Gene Expression between Tumor and Normal Samples. The cancer related public databases Oncomine (<https://www.oncomine.org/>) was used to investigate the mRNA expression level of MTs in tumor and normal tissue [24]. In the Oncomine database, all members of MT family were retrieved and the differential gene analysis (GC versus normal) combined with mRNA data type were chosen. In this study, the Student's t-test was used to generate *p* values of comparison. The cutoff *p* value and fold change were defined as 0.01 and 2.

The expression of MTs between tumor and normal gastric tissue was also studied using the GEPIA browser (<http://gepia.cancer-pku.cn/>), which is an online tool for estimating mRNA expression based on The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects [25]. Box and stage plotting analyses were processed on this database. The cutoff *p* value was defined as 0.01.

2.2. Analysis of Prognostic Values of MT Members in GC Patients. The association among MTs expression and the overall survival (OS), first progression (FP), and postprogression survival (PPS) in GC was analyzed by data mining in the Kaplan-Meier plotter database (<http://kmplot.com>), which is an online database that enables assessment of survival related biomarkers download from Gene Expression Omnibus (GEO) [26]. In this study, clinical data including subtypes, stage, differentiation, HER2 status, and treatment was collected.

SurvExpress (<http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp>), a large online database that enables comparison and validation of survival related biomarkers for cancer outcomes was used when the survival data of some MT family members were not available in Kaplan-Meier plotter [27]. The parameters chosen for survival analysis were as follows: larger stomach adenocarcinoma (STAD) sample size (>200 patient), dataset from TCGA, duplicated genes-show all, data-uniformized. The median MTs expression was used as the cutoff. Hazard ratios with 95% CI and log-rank *p* value were calculated.

2.3. Comparison of MTs Gene Methylation between Tumor versus Nontumor Tissues and Analysis of Relationship between Methylation and mRNA Expression in GC from MethHC. DNA methylation of MTs between tumor and normal tissue was compared through the human pan-cancer methylation database-MethHC (<http://methhc.mbc.nctu.edu.tw/>), which is a database focused on the DNA methylation of human diseases from TCGA [28]. In addition, the correlation between MTs methylation and its mRNA expression in GC patients was also analyzed using MethHC. In this study, the gene region was chosen as promoter and the methylation level evaluation method was defined as average.

2.4. Analysis of MTs Gene Mutations and Associated Network in GC from TCGA. Clinical data from TCGA database for GC patients were downloaded and processed in Microsoft Excel and manually checked on the base of the primary site of tumor onset in a bid to exclude non-GC patients. Meanwhile, the information of GC downloaded in the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>) was processed to analyze the presence of mutations, EBV infection rate, and explore the associated network of MTs in GC [29, 30]. GeneMANIA, a flexible, accurate database that can generate network information based on genes inputted including protein and genetic interactions, pathways, coexpression, colocalization, and protein domain similarity [31], was used to find additional genes or proteins related to MTs.

3. Results

3.1. Downregulation of MTs mRNA in Patients with GC. Oncomine and GEPIA databases data was used to examine differential levels of MTs mRNA between gastric cancer and normal gastric tissue. In addition to GC, difference of MTs mRNA in other cancers and their paired normal tissue was also assessed in Oncomine database. Among

3.2. Prognostic Features of MTs in Patients with GC. Prognostic features of MTs mRNA for GC patients including OS, FP, and PPS were investigated, respectively, through data mining in Kaplan-Meier plotter. It could be seen that almost all MTs prognostic feature can be searched out in GC patients other than MT1A and MT1B, both of which were analyzed alternatively by using SurvExpress database. There was no significant correlation in gastric cancer between OS and either MT1A or MT1B (supplementary Figure 2). Among these MTs available in the Kaplan-Meier, 6, 8, and 5 isoforms mRNA were significantly associated with OS, FP,

As per the Lauren's classification of stomach adenocarcinoma, GC was classified into three subtypes: intestinal type, diffuse type, and mixed type. As such, prognostic value of MTs isoforms was also determined in different GC subtypes using Kaplan-Meier plotter online tool. The data from individual probe indicated that 8 out of 9 available MT members mRNA expression were correlated with OS in GC intestinal type ($P < 0.05$; Table 2). Furthermore, the majority of them (5/8) were with better prognosis (OS) (data was not shown). In addition, other survival analysis revealed that clinicopathological features including clinical stage, differentiation, HER2 status, and treatment were significant

FIGURE 2: The distinct expression of MT family isoforms between cancer and normal tissues in GC patients (GEPIC). *Notes:* Box plots derived from gene expression data in GEPIC comparing expression of a specific MT isoform in GC tissue and normal tissues; the P value was set up at 0.05. *Abbreviations:* GC: gastric cancer; STAD: stomach Adenocarcinoma; T: tumor; N: normal.

parameters affecting the survival time of GC patients (Table 3, supplementary Tables 1–3).

3.3. DNA Methylation of MTs and Its Correlation with mRNA Expression in GC Patients. To identify the role of methylation in regulating MTs expression in patients with GC, MethHC was utilized to explore the level of methylation in promoter region and its relationship with mRNA expression of MT genes. Among all types of MT, the difference of methylation level between cancer and normal samples was statistically

significant except gene MT1E ($P < 0.05$, Figure 4). The majority of MTs (8/11) in cancer exhibited extraordinarily methylated variation in promoter region compared to normal tissue ($P < 0.005$, Figure 4). Notably, DNA methylation of some MT isoforms in gastric cancer, like MT1A, MT1B, MT1H, MT1M, MT3, and MT4, was higher than their paired normal tissue except remaining isoforms (Figure 4). Additionally, an inverse correlation between DNA methylation and mRNA expression of most isoforms of MT in GC was observed other than MT1A and MT4 isoforms ($P < 0.001$, Table 4).

TABLE 1: The transcription levels of MT family isoforms between different types of GC and normal tissues (ONCOMINE).

MT family members	Types of GC vs. normal	Fold change	t-Test	P value	Reporter
MT1A	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.939	-5.52	1.48E-06	ILMN-1691156
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.151	-6.36	1.04E-07	ILMN-1691156
	Gastric Mixed Adenocarcinoma vs. Normal	-3.053	-3.47	2.00E-03	ILMN-1691156
	Gastric Adenocarcinoma vs. Normal	-2.255	-0.99	0.196	ILMN-1691156
MT1B	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.496	-7.43	3.42E-09	IMAGE:232772
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.037	-4.43	5.52E-05	IMAGE:232772
	Gastric Mixed Adenocarcinoma vs. Normal	-2.321	-4.43	2.26E-04	IMAGE:232772
	Gastric Cancer vs. Normal	-1.327[▲]	-1.65	0.051	3662190
	Gastric Mixed Adenocarcinoma vs. Normal	-1.111[▲]	-1.31	0.102	ILMN-1733758
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.065[▲]	-0.73	0.236	ILMN-1733758
	Diffuse Gastric Adenocarcinoma vs. Normal	1.025[*]	0.223	0.588	ILMN-1733758
	Gastric Adenocarcinoma vs. Normal	1.326[*]	0.793	0.76	ILMN-1733758
MT1E	Gastric Mixed Adenocarcinoma vs. Normal	-3.006	-7.8	1.16E-08	ILMN-1718968
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-3.014	-7.81	1.99E-09	ILMN-1718968
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.042	-8.23	6.09E-10	ILMN-1718968
	Gastric Adenocarcinoma vs. Normal	-2.524	-4.05	0.005	ILMN-1718968
	Gastric Cancer vs. Normal	-3.942	-3.17	9.14E-04	3662139
	Gastric Mixed Adenocarcinoma vs. Normal	-5.468	-5.12	0.005	212859-x-at
	Gastric Cancer vs. Normal	-2.435	-2.79	0.006	212859-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-1.97[▲]	-2.66	0.018	212859-x-at
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.74[▲]	-3.17	0.001	212859-x-at
MT1F	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.011	-10.9	7.66E-14	IMAGE:78353
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.821	-6.8	6.50E-08	IMAGE:78353
	Gastric Mixed Adenocarcinoma vs. Normal	-4.273	-4.69	3.35E-04	IMAGE:245990
	Diffuse Gastric Adenocarcinoma vs. Normal	-4.486	-8.37	2.13E-10	ILMN-1718766
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-3.911	-6.22	1.69E-07	ILMN-1718766
	Gastric Mixed Adenocarcinoma vs. Normal	-4.355	-3.73	0.001	ILMN-1718766
	Gastric Mixed Adenocarcinoma vs. Normal	-4.283	-10.5	4.58E-06	213629-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.712	-4.1	0.003	213629-x-at
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.095	-4.22	5.69E-05	217165-x-at
	Gastric Cancer vs. Normal	-3.148	-3.12	0.003	213629-x-at
	Gastric Adenocarcinoma vs. Normal	-2.514	-0.81	0.237	ILMN-1718766
MT1G	Gastric Cancer vs. Normal	-3.231	-6.53	4.28E-10	3692999
	Diffuse Gastric Adenocarcinoma vs. Normal	-4.274	-6.82	4.25E-08	IMAGE:202535
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.68	-10	1.04E-12	IMAGE:202535
	Gastric Mixed Adenocarcinoma vs. Normal	-5.508	-5.68	7.17E-05	IMAGE:202535
	Diffuse Gastric Adenocarcinoma vs. Normal	-4.092	-6.15	1.43E-04	204745-x-at
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.636	-5.41	1.02E-06	204745-x-at
	Gastric Mixed Adenocarcinoma vs. Normal	-6.734	-8.01	3.57E-04	204745-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-8.187	-8.02	1.19E-10	ILMN-1715401
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-6.637	-6.24	2.22E-07	ILMN-1715401
	Gastric Mixed Adenocarcinoma vs. Normal	-4.742	-3.31	0.003	ILMN-1715401
	Gastric Cancer vs. Normal	-4.655	-3.41	0.001	210472-at
	Gastric Adenocarcinoma vs. Normal	-3.824	-1.15	0.165	ILMN-1715401
MT1H	Gastric Intestinal Type Adenocarcinoma vs. Normal	-4.137	-9.59	1.06E-12	IMAGE:214162
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.314	-5.99	1.13E-06	IMAGE:214162
	Gastric Mixed Adenocarcinoma vs. Normal	-4.151	-4.5	8.45E-04	IMAGE:214162
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.076	-5.1	4.59E-04	206461-x-at
	Gastric Mixed Adenocarcinoma vs. Normal	-4.261	-7.53	1.72E-04	206461-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-6.768	-6.77	5.16E-08	ILMN-2124802
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.882	-5.4	2.04E-06	ILMN-2124802
	Gastric Mixed Adenocarcinoma vs. Normal	-4.122	-2.75	0.008	ILMN-2124802
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.84[▲]	-3.76	2.21E-04	206461-x-at
	Gastric Adenocarcinoma vs. Normal	-2.701	-0.85	0.228	ILMN-2124802
	Gastric Cancer vs. Normal	-1.32[▲]	-2.25	0.013	2462589

TABLE 1: Continued.

MT family members	Types of GC vs. normal	Fold change	t-Test	P value	Reporter
MT1M	Gastric Cancer vs. Normal	-4.451	-7.56	1.68E-12	3662150
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.442	-11.2	8.37E-17	IMAGE:126458
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.75	-6.3	9.03E-07	IMAGE:126458
	Gastric Mixed Adenocarcinoma vs. Normal	-6.244	-6.14	1.15E-04	IMAGE:126458
	Diffuse Gastric Adenocarcinoma vs. Normal	-8.169	-9	7.18E-10	ILMN-1657435
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.42	-6.12	2.48E-07	ILMN-1657435
	Gastric Mixed Adenocarcinoma vs. Normal	-3.749	-3.03	0.004	ILMN-1657435
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-5.088	-6.1	2.23E-07	217546-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-4.402	-3.57	0.006	217546-at
	Gastric Cancer vs. Normal	-10.35	-3.32	0.003	217546-at
MT1X	Gastric Adenocarcinoma vs. Normal	-1.999[▲]	-0.87	0.221	ILMN-1657435
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-3.75	-9.04	8.45E-12	IMAGE:297392
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.85	-5.07	1.17E-05	IMAGE:297392
	Gastric Mixed Adenocarcinoma vs. Normal	-3.223	-4.26	6.15E-04	IMAGE:297392
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-4.098	-6.29	1.63E-07	ILMN-1775170
	Diffuse Gastric Adenocarcinoma vs. Normal	-3.782	-6.42	1.60E-07	ILMN-1775170
	Gastric Mixed Adenocarcinoma vs. Normal	-3.21	-3.71	8.60E-04	ILMN-1775170
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.371	-4.44	0.001	208581-x-at
	Gastric Mixed Adenocarcinoma vs. Normal	-3.11	-4.86	0.004	208581-x-at
	Gastric Cancer vs. Normal	-3.261	-4.92	1.09E-06	3662247
MT2A	Gastric Adenocarcinoma vs. Normal	-2.329	-1.1	0.172	ILMN-1775170
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.55[▲]	-2.95	0.002	208581-x-at
	Gastric Cancer vs. Normal	-1.99[▲]	-2.18	0.021	208581-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.117	-4.32	0.001	212185-x-at
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.308	-4.56	2.50E-05	ILMN-1686664
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.153	-3.85	2.25E-04	ILMN-1686664
	Gastric Mixed Adenocarcinoma vs. Normal	-2.68	-3.67	9.96E-04	ILMN-1686664
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.42[▲]	-2.7	0.005	208581-x-at
	Gastric Adenocarcinoma vs. Normal	-1.89[▲]	-0.86	0.224	ILMN-1686664
	Gastric Cancer vs. Normal	-1.87[▲]	-2.33	0.015	212185-x-at
MT3	Gastric Intestinal Type Adenocarcinoma vs. Normal	-2.85	-8.47	1.47E-10	IMAGE:2019011
	Diffuse Gastric Adenocarcinoma vs. Normal	-2.312	-5.22	5.48E-06	IMAGE:2019011
	Gastric Mixed Adenocarcinoma vs. Normal	-2.688	-4.68	2.23E-04	IMAGE:2019011
	Diffuse Gastric Adenocarcinoma vs. Normal	-1.21[▲]	-3.71	3.47E-04	ILMN-1675947
	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.14[▲]	-1.89	0.034	ILMN-1675947
	Gastric Mixed Adenocarcinoma vs. Normal	-1.11[▲]	-0.77	0.229	ILMN-1675947
	Gastric Adenocarcinoma vs. Normal	1.107[*]	0.315	0.614	ILMN-1675947
	Gastric Cancer vs. Normal	-1.24[▲]	-2.81	0.003	3662093
	Diffuse Gastric Adenocarcinoma vs. Normal	-1.79[▲]	-1.63	0.079	205970-at
	Gastric Mixed Adenocarcinoma vs. Normal	-1.97[▲]	-2.04	0.061	205970-at
MT4	Gastric Intestinal Type Adenocarcinoma vs. Normal	-1.21[▲]	-1.33	0.096	205970-at
	Gastric Cancer vs. Normal	-1.19[▲]	-0.57	0.288	205970-at
	Gastric Cancer vs. Normal	-2.723	-5.62	5.26E-08	3662086
	Gastric Mixed Adenocarcinoma vs. Normal	1.02[*]	0.673	0.744	ILMN-1745345
	Diffuse Gastric Adenocarcinoma vs. Normal	1.018[*]	1.026	0.844	ILMN-1745345
	Gastric Intestinal Type Adenocarcinoma vs. Normal	1.032[*]	1.191	0.879	ILMN-1745345
	Gastric Adenocarcinoma vs. Normal	1.461[*]	1.104	0.825	ILMN-1745345

Notes: P value was analyzed using the t-test. The bold font indicates that the difference was not statistically significant between the GC and normal tissue group. The bold font with symbol “[▲]” indicates the fold change was no more than 2 folds. The bold font with symbol “^{*}” indicates the transcription level of MTs in gastric cancer was slightly higher than normal tissue.

3.4. MTs Mutations and Associated Network in GC Patients. Genetic mutations of MT family members were analyzed through cBioPortal online tool for GC patients. A total of 1443 patients from seven datasets of stomach adenocarcinoma

were analyzed. Among these seven datasets, mutation rate of MTs calculated in three datasets was 1.36% (6/440), 2.51% (12/478), and 3.39% (10/295), respectively, and no statistically significant difference was observed for OS and DFS between

FIGURE 3: Continued.

PPS<0.05

FIGURE 3: The prognostic values of mRNA level of MTs in all GC patients (Kaplan-Meier plotter). *Notes:* Kaplan-Meier plots show the association between the expression of MTs and OS, FP and PPS in GC patients, respectively, with statistical significance. A1–3: Prognostic HRs of individual MT isoform in all gastric cancer for OS, FP, and PPS. (b) OS curves of MT1F (Affymetrix ID:217165.x at); MT1G (Affymetrix ID:210472.x at); MT1H (Affymetrix ID:206461.x at); MT1X (Affymetrix ID:204326.x at); MT3 (Affymetrix ID:205970.x at); MT4 (Affymetrix ID:217395.x at). (c) FP Curves of MT1E (Affymetrix ID:212859.x at); MT1F; MT1G; MT1H; MT1M (Affymetrix ID:217546.x at); MT1X; MT3; MT4. (d) PPS curves of MT1G; MT1X; MT2A (Affymetrix ID:212185.x at); MT3; MT4. *Abbreviations:* OS: overall survival; FP: first progression; PPS: postprogression survival; GC: gastric cancer; HR: hazard ratio.

cases with and without MT mutation in gastric cancer (data was not showed). The percentage of genetic mutation in MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, MT2A, MT3, and MT4 was 0.6% (deep deletion), 0.9% (0.21% missense mutation, 0.62% deep deletion), 0.6% (deep deletion), 0.6% (deep deletion), 0.9% (0.28% missense mutation, 0.62% deep deletion), 0.6% (deep deletion), 1.1% (0.42% missense mutation, 0.62% Deep Deletion), 0.6% (deep depletion), 0.8% (0.14% missense mutation, 0.62% deep depletion), 0.7% (0.07% truncating mutation, 0.62% deep depletion), and 0.9% (0.27% truncating mutation, 0.62 deep depletion) (Figure 5(a)). Data from in situ hybridization (ISH) revealed that 20% (40/200) were EBV positive. In addition, crossing data of primary site showed that 37.1% (161/434) of these tumors were located at the antrum, followed by fundus/body (35%), cardia/proximal (14.3%), gastroesophageal junction (10.6%), and the unknowable site (3%) (Figure 5(a)).

The network established in cBioPortal demonstrated that FOS, JUN, and SP1 control the expression of MT2A, whereas HLA-DRA and HLA-DRB1 control the expression of FOS. FOS controls the expression of JUN; meanwhile, B2M and HLA-B control the state change of JUN (Figure 5(b)). Furthermore, another network for MTs with the structure or

function of neighboring genes constructed from GeneMANIA showed that other 20 genes—MT1HL1, BBS2, AAMDC, CD160, MARC2, TMEM51, IYD, LGALS2, NEURL3, ASPA, PTGDR, C11orf52, TMEM14C, SPPI, SYMM, ZSWIM5, TNN, SORBS3, ACPP, and TLR3—were associated closely with MTs. The result showed that all MTs protein shared protein domains with each other and particularly shared protein domains even with another protein named MT1H1 (Figure 5(c)).

4. Discussion

Up to date, accumulating studies were emerging to investigate MTs expression and their roles in malignant tumors, but only a minority of MT isoforms were evaluated in gastric cancer and no unanimous agreement was reached. In an immunohistochemical analysis, Ebert and his colleagues showed overexpression of MT in GC tissues, independent of tumor stage, differentiation, or tumor type [14]. Similar outcome of MT in GC was also reported by other groups [17, 32]. On the contrary, several studies reported a lower MT expression in GC specimens than normal mucosae [15, 16, 18]. Until now, a minority of individual isoform of MTs

TABLE 2: The prognostic values of MT isoforms in different pathological subtypes of GC patients (Kaplan-Meier plotter).

MT family	Lauren classification	OS				PPS			
		cases	HR	95%CI	P value	cases	HR	95%CI	P value
MT1E	intestinal	320	0.67	0.49-0.92	0.013	192	1.39	0.92-2.1	0.12
	diffuse	241	0.55	0.38-0.79	0.0011	176	0.53	0.34-0.83	0.0045
	mixed	32	5.92	0.77-45.35	0.053	16	–	–	–
MT1F	intestinal	320	0.63	0.46-0.88	0.0056	192	0.7	0.45-1.09	0.11
	diffuse	241	0.62	0.44-0.88	0.0063	176	0.48	0.3-0.77	0.0019
	mixed	32	2.02	0.68-5.99	0.2	16	–	–	–
MT1G	intestinal	320	1.99	1.42-2.8	0.00005	192	2.6	1.7-3.97	4.3E-05
	diffuse	241	1.83	1.18-2.82	0.006	176	1.53	1.03-2.28	0.034
	mixed	32	3.32	1.3-9.82	0.021	16	–	–	–
MT1H	intestinal	320	0.7	0.5-1	0.046	192	0.63	0.4-1.0	0.047
	diffuse	241	0.55	0.39-0.77	0.00053	176	0.54	0.36-0.79	0.0015
	mixed	32	0.33	0.07-1.47	0.13	16	–	–	–
MT1M	intestinal	320	0.59	0.42-0.84	0.0027	192	1.48	0.98-2.25	0.061
	diffuse	241	0.59	0.39-0.89	0.011	176	0.54	0.34-0.84	0.0051
	mixed	32	1.57	0.57-4.36	0.38	16	–	–	–
MT1X	intestinal	320	0.58	0.42-0.82	0.0015	192	0.65	0.42-0.99	0.041
	diffuse	241	0.57	0.4-0.79	0.00087	176	0.56	0.38-0.83	0.0029
	mixed	32	0.49	0.14-1.75	0.26	16	–	–	–
MT2A	intestinal	320	1.27	0.93-1.75	0.13	192	1.49	0.99-2.25	0.055
	diffuse	241	0.59	0.41-0.86	0.0047	176	0.65	0.44-0.97	0.035
	mixed	32	0.52	0.18-1.51	0.22	16	–	–	–
MT3	intestinal	320	2.34	1.69-3.26	1.8E-06	192	1.79	1.18-2.7	0.0051
	diffuse	241	1.24	0.83-1.86	0.29	176	1.23	0.78-1.94	0.37
	mixed	32	1.43	0.49-4.2	0.51	16	–	–	–
MT4	intestinal	320	2.58	1.87-3.56	1.8E-08	192	2.48	1.4-4.4	0.0013
	diffuse	241	0.72	0.52-1.02	0.06	176	1.5	0.96-2.33	0.07
	mixed	32	2.8	1.01-7.77	0.038	16	–	–	–

Notes: P value was analyzed using the survival analysis test. The fold indicates that the difference was statically significant. The P value was set up at 0.05. Abbreviations: GC: gastric cancer; OS: overall survival; PPS: postprogression survival; HR: hazard ratio.

involved in GC was reported, such as MT1A, MT2A, and MT3 [13, 14, 19, 20, 33, 34]. The upregulation of MT3 in GC of one individual study was consistent with the result demonstrated in our current study [33]. MT2A expression in GC reported by pan’s group was in accordance with the outcome of public database datamined in our study [13, 20, 34], but a paradoxical viewpoint was also reported [14]. With respect to other MT isoforms in GC, pan’s group also did parts of the work, but no significant difference was found between tumor and nontumor tissue and even no MT1B expression was detected in gastric cells and tissues [34]. Taken together, relatively limited studies focused on MT family, especially individual MT isoform in GC and more researches are needed to make specific conclusions for each MT isoform in GC.

MTs overexpression was frequently reported to be associated with poor prognosis in a wide range of human cancers, such as hepatocellular carcinoma, breast cancer, glioblastoma, oral cancer, and melanoma [23, 35–38]. Although the prognostic role of MTs in gastric cancer was also evaluated in several studies, it is still hard to conclude what exact value they possessed. For instance, several studies argued that

no association was discovered among MT expression and tumor stage, differentiation, and survival prognosis in gastric cancer [14, 18, 32], while another research demonstrated that MT overexpression was associated with a poor survival rate [17]. In the current study, data showed that some specific MT isoforms like MT1E, MT1G, MT1H, and MT1X were associated with OS. Notably, the result reported by one group showed that loss of MT2A was associated with poor prognosis and advanced TNM stage, which was not in accordance with the findings of our study [13, 19, 20].

The broad heterogeneity of MT expression and its prognostic role in gastric cancer can be simplistically attributed to shortage of case numbers and different ethnicity of patients recruited or distinct transcripts of MT gene adopted in their studies. However, more important reason may be the facts that MT exists as a mixture of variable forms. Because of the high structure similarity of MTs, present proteomic methods lack the ability to distinguish all subisoforms. For example, the antibodies used in many studies could not specify MT1 and MT2 isoform due to their physical-chemical homology [39]. This speculation seems to be verified by the

TABLE 3: The prognostic values of MT isoforms in GC patients with different clinical stage (Kaplan-Meier plotter).

MT family	clinical stage	OS				PPS			
		cases	HR	95%CI	P value	cases	HR	95%CI	P value
MT1E	I	67	0.43	0.16-1.16	0.085	31	0.1	0.02-0.71	0.007
	II	140	0.63	0.32-1.23	0.17	105	0.6	0.26-1.35	0.21
	III	305	0.72	0.54-0.96	0.026	142	0.7	0.45-1.1	0.12
	IV	148	0.72	0.46-1.14	1.14	104	1.3	0.84-2.07	0.22
MT1F	I	67	0.27	0.1-0.72	0.005	31	0.1	0.02-0.69	0.006
	II	140	0.54	0.27-1.08	0.075	105	0.6	0.27-1.41	0.25
	III	305	0.66	0.49-0.88	0.004	142	0.7	0.44-1.03	0.068
	IV	148	0.7	0.44-1.11	0.12	104	1.3	0.77-2.25	0.31
MT1G	I	67	2.87	0.92-8.96	0.058	31	6.6	6.25-34.15	0.011
	II	140	1.69	0.88-3.23	0.11	105	2	0.79-5.24	0.13
	III	305	1.68	1.26-2.23	4E-04	142	2	1.29-3.02	0.001
	IV	148	1.78	1.16-2.73	0.007	104	2.4	1.46-3.97	4E-04
MT1H	I	67	2	0.71-5.57	0.18	31	0.2	0.02-1.79	0.12
	II	140	0.54	0.28-1.04	0.061	105	0.5	0.25-1.07	0.07
	III	305	0.75	0.57-1.01	0.054	142	0.7	0.45-1.04	0.076
	IV	148	0.62	0.41-0.95	0.027	104	1.3	0.74-2.1	0.41
MT1M	I	67	2.34	0.67-8.23	0.17	31	2.8	0.55-14.59	0.2
	II	140	0.82	0.44-1.52	0.52	105	0.7	0.37-1.42	0.35
	III	305	0.73	0.52-1.02	0.067	142	0.7	0.45-1.11	0.13
	IV	148	0.73	0.46-1.15	0.17	104	1.5	0.92-2.32	0.11
MT1X	I	67	0.29	0.1-0.8	0.011	31	0	—	0.002
	II	140	0.49	0.22-1.11	0.081	105	0.6	0.29-1.33	0.22
	III	305	0.61	0.46-0.81	7E-04	142	0.6	0.39-0.92	0.017
	IV	148	0.66	0.45-0.99	0.041	104	1.4	0.79-2.35	0.27
MT2A	I	67	0.35	0.13-0.93	0.028	31	0.1	0.02-0.67	0.005
	II	140	0.57	0.28-1.16	0.12	105	0.6	0.27-1.43	0.26
	III	305	0.79	0.59-1.05	0.11	142	0.7	0.47-1.16	0.19
	IV	148	0.78	0.51-1.18	0.24	104	1.5	0.93-2.27	0.095
MT3	I	67	1.79	0.61-5.21	0.28	31	3.5	0.76-16.1	0.089
	II	140	2.07	1.14-3.74	0.014	105	2	0.99-3.82	0.049
	III	305	2.05	1.48-2.83	1E-05	142	2.1	1.35-3.22	7E-04
	IV	148	1.38	0.89-2.14	0.14	104	0.6	0.35-0.93	0.023
MT4	I	67	1.87	0.69-5.04	0.21	31	2.7	0.32-23.29	0.34
	II	140	1.3	0.62-2.71	0.49	105	1.7	0.81-3.7	0.15
	III	305	1.88	1.41-2.52	2E-05	142	1.9	1.21-2.95	0.004
	IV	148	1.29	0.88-1.91	0.19	104	1.3	0.81-2.04	0.29

Notes: P value was analyzed using the survival analysis test. The fold indicates that the difference was statically significant. The P value was set up at 0.05. Abbreviations: GC: gastric cancer; OS: overall survival; PPS: postprogression survival; HR: hazard ratio.

TABLE 4: The correlation between DNA methylation and mRNA expression in the MT gene members of GC patients (MethHC).

Variable	Methylation										
	MT1A	MT1B	MT1E	MT1F	MT1G	MT1H	MT1M	MT1X	MT2A	MT3	MT4
mRNA expression	r=0.007 p=4.44	r=-0.123 p<0.001*	r=-0.279 p<0.001*	r=-0.116 p<0.001*	r=-0.158 p<0.001*	r=-0.230 p<0.001*	r=-0.187 p<0.001*	r=0.010 p<0.001*	r=-0.160 p<0.001*	r=-0.248 p<0.001*	r=-0.02 p=0.59

Notes: “*” indicates statistical significance with P<0.001. Abbreviation: GC: gastric cancer.

FIGURE 4: The distinct methylation of MT isoforms in promoter region between cancer and normal tissues in GC patients (MethHC). *Notes:* box plots in red color represent cancer samples and those in green color represent normal samples. GC: gastric cancer; “*” indicates being statistically significant with $P < 0.05$. “**” indicates being statistically significant with $P < 0.005$.

phenomenon mentioned above that the change in MT1/2 protein expression was different from single MT isoforms and different MT isoform plays distinct function in cell activities [38, 39]. Although the antibodies specific to MT1A, MT1G, and MT3 were available in market [9, 40], distinguishing of MTs by using antibodies is even more tricky.

DNA methylation is an important epigenetic modification in cancer formation by silencing tumor suppressor genes. A wide range of studies investigated MTs promoter methylation in some cancer types, but limiting studies about MTs methylation in gastric cancer were published up to now [21, 41–43]. In line with MT3 hypermethylation in gastric

cancer showed by Deng et al., our study also showed that MT3 was highly hypermethylated compared with normal gastric tissue [33]. In the present study, we demonstrated that half of MT isoforms in GC were highly methylated in the promotor region except MT1E and that there was an inverse correlation between DNA methylation and mRNA expression of most isoforms of MT other than MT1A and MT4 isoforms. Therefore, it is not difficult to conclude that methylation in MTs gene promoter region partially contributed to their reduced expression in GC. In addition, our study revealed that MT genes are very rarely mutated and no statistically significant difference was observed for OS and disease-free survival (DFS) between cases with and without alteration of MTs in gastric cancer. The Epstein-Barr Virus (EBV), the second pathogen associated with GC, was found in approximately 20% of the samples in the present study, which was similar to previous studies [44–46]. Meanwhile, the outcomes in our study that GC located most frequently at the antrum are in line with previous studies [47–49]. Moreover, we established networks related to MT family to explore other genes involved in regulatory relationship between them.

In summary, all these findings indicated that MTs were nearly downregulated in GC tissue and their prognostic values in GC were dependent on single isoform of MT, which need to be determined further in de facto cohort studies. As such, our study offered comprehensive evidences to evaluate the possible regulating function of MTs in GC which may help for further discovering MTs as potential diagnostic or prognostic biomarkers and therapeutic target for GC in the future.

5. Study Limitations

However, the present study was not without limitations. First, all the data analyzed in our study was obtained from different online databases, which might cause background heterogeneity. Additionally, the study did not conduct experiments to validate the results obtained from silicobioinformatic analysis based on online databases. Therefore, more elaborate studies with focus on various MT isoforms expression and prognostic value in GC need to be performed in the future.

Data Availability

All data like figures and tables used to support the findings of this study are included within the article. All data like supplementary figures and tables used to support the findings of this study are included within the supplementary information materials. All unavailable data used to support the findings of this study can be seen on related database online. We did not release them not because we did not give the original data but we gave it in another form which could not reflect it directly.

Conflicts of Interest

The authors report no conflicts of interest in this work.

Authors' Contributions

Mingfu Tong and Wenquan Lu contributed equally to this work.

Acknowledgments

The work was funded by the Natural Science Foundation of China (No. 81430072, to Daiming Fan), the Scientific Fund for Innovative Research Groups of the National Natural Science Foundation of China (No. 81421003, to Daiming Fan), and Fundamental Research Funds for National Center for Clinical Medicine of Digestive Diseases (No. 2015BAI13B07, to Daiming Fan).

Supplementary Materials

Supplementary Figure 1: the correlation between the expression of MTs and tumor stages in GC patients (GEPIA). Supplementary Figure 2: the prognostic values with no significance of mRNA level of MTs in all GC patients (SurvExpress, Kaplan-Meier plotter). Supplementary Tables 1–3: the prognostic values of MT isoforms in GC patients with different differentiation, HER2 status, and treatment (Kaplan-Meier plotter). (*Supplementary Materials*)

References

- [1] International Agency for Research on Cancer, "World Health Organization: The Global Cancer Observatory (GCO)," 2019, <http://globocan.iarc.fr/Default.aspx>.
- [2] S. G. Thrumurthy, M. A. Chaudry, I. Chau, and W. Allum, "Does surgery have a role in managing incurable gastric cancer?" *Nature Reviews Clinical Oncology*, vol. 12, no. 11, pp. 676–682, 2015.
- [3] M. A. Shah, R.-H. Xu, Y.-J. Bang et al., "HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma," *Journal of Clinical Oncology*, vol. 35, no. 22, pp. 2558–2567, 2017.
- [4] C. D. Klaassen, J. Liu, and B. A. Diwan, "Metallothionein protection of cadmium toxicity," *Toxicology and Applied Pharmacology*, vol. 238, no. 3, pp. 215–220, 2009.
- [5] A. West, R. Stallings, C. Hildebrand, R. Chiu, M. Karin, and R. Richards, "Human metallothionein genes: structure of the functional locus at 16q13," *Genomics*, vol. 8, no. 3, pp. 513–518, 1990.
- [6] A. Moleirinho, J. Carneiro, R. Matthiesen et al., "Gains, losses and changes of function after gene duplication: study of the metallothionein family," *PLoS ONE*, vol. 6, no. 4, p. e18487, 2011.
- [7] M. Ryvolova, V. Adam, and R. Kizek, "Analysis of metallothionein by capillary electrophoresis," *Journal of Chromatography A*, vol. 1226, pp. 31–42, 2012.
- [8] J. C. Mougeot, Z. Bahrani-Mostafavi, J. C. Vachris et al., "Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis," *Journal of Molecular Biology*, vol. 358, no. 1, pp. 310–329, 2006.

- [9] B. Pula, T. Tazbierski, A. Zamirska et al., "Metallothionein 3 expression in normal skin and malignant skin lesions," *Pathology & Oncology Research*, vol. 21, no. 1, pp. 187–193, 2015.
- [10] I. Alkamal, O. Ikromov, A. Tölle et al., "An epigenetic screen unmasks metallothioneins as putative contributors to renal cell carcinogenesis," *Urologia Internationalis*, vol. 94, no. 1, pp. 99–110, 2015.
- [11] A. Nguyen, Z. Jing, P. S. Mahoney et al., "In vivo gene expression profile analysis of metallothionein in renal cell carcinoma," *Cancer Letters*, vol. 160, no. 2, pp. 133–140, 2000.
- [12] E. T. Soo, C. NG, G. W. Yip et al., "Differential expression of metallothionein in gastrointestinal stromal tumors and gastric carcinomas," *The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology*, vol. 294, no. 2, pp. 267–272, 2011.
- [13] Y. Pan, S. Lin, R. Xing et al., "Epigenetic upregulation of metallothionein 2A by diallyl trisulfide enhances chemosensitivity of human gastric cancer cells to docetaxel through attenuating NF- κ B activation," *Antioxidants & Redox Signaling*, vol. 24, no. 15, pp. 839–854, 2016.
- [14] M. P. Ebert, T. Gunther, J. Hoffmann et al., "Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer," *Cancer Research*, vol. 60, no. 7, pp. 1995–2001, 2000.
- [15] G. Tuccari, G. Giuffrè, F. Arena, and G. Barresi, "Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa," *Histology and Histopathology*, vol. 15, no. 4, pp. 1035–1041, 2000.
- [16] A. M. Janssen, W. van Duijn, M. M. Oostendorp-van de Ruit et al., "Metallothionein in human gastrointestinal cancer," *The Journal of Pathology*, vol. 192, no. 3, pp. 293–300, 2000.
- [17] G. Galizia, F. Ferraraccio, E. Lieto et al., "p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate," *Journal of Surgical Oncology*, vol. 93, no. 3, pp. 241–252, 2006.
- [18] A. M. Janssen, W. van Duijn, F. J. Kubben et al., "Prognostic significance of metallothionein in human gastrointestinal cancer," *Clinical Cancer Research*, vol. 8, no. 6, pp. 1889–1896, 2002.
- [19] J. An, Y. Pan, Z. Yan et al., "MiR-23a in amplified 19p13.13 loci targets metallothionein 2A and promotes growth in gastric cancer cells," *Journal of Cellular Biochemistry*, vol. 114, no. 9, pp. 2160–2169, 2013.
- [20] S. Lin, X. Wang, Y. Pan et al., "Transcription factor myeloid zinc-finger 1 suppresses human gastric carcinogenesis by interacting with metallothionein 2A," *Clinical Cancer Research*, vol. 25, no. 3, pp. 1050–1062, 2019.
- [21] W. J. Faller, M. Rafferty, S. Hegarty et al., "Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis," *Melanoma Research*, vol. 20, no. 5, pp. 392–400, 2010.
- [22] Y. Koga, M. Pelizzola, E. Cheng et al., "Genome-wide screen of promoter methylation identifies novel markers in melanoma," *Genome Research*, vol. 19, no. 8, pp. 1462–1470, 2009.
- [23] E. Emri, K. Egervari, T. Varvolgyi et al., "Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma," *Journal of the European Academy of Dermatology and Venereology*, vol. 27, no. 3, pp. e320–e327, 2013.
- [24] D. R. Rhodes, J. Yu, K. Shanker et al., "ONCOMINE: a cancer microarray database and integrated data-mining platform," *Neoplasia*, vol. 6, no. 1, pp. 1–6, 2004.
- [25] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, no. 1, pp. W98–W102, 2017.
- [26] A. M. Szász, A. Lánckzy, Á. Nagy et al., "Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients," *Oncotarget*, vol. 7, no. 31, pp. 49322–49333, 2016.
- [27] R. Aguirre-Gamboa, H. Gomez-Rueda, E. Martínez-Ledesma et al., "SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis," *PLoS ONE*, vol. 8, no. 9, p. e74250, 2013.
- [28] W. Huang, S. Hsu, H. Huang et al., "MethHC: a database of DNA methylation and gene expression in human cancer," *Nucleic Acids Research*, vol. 43, no. D1, pp. D856–D861, 2015.
- [29] J. Gao, B. A. Aksoy, and U. Dogrusoz, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal," *Science Signaling*, vol. 6, no. 269, p. 11, 2013.
- [30] E. Cerami, J. Gao, U. Dogrusoz et al., "The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data," *Cancer Discovery*, vol. 2, no. 5, pp. 401–404, 2012.
- [31] D. W. Farley, S. L. Donaldson, O. Comes et al., "The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function," *Nucleic Acids Research*, vol. 38, no. 2, pp. W214–W220, 2010.
- [32] N. Monden, S. Abe, I. Sutoh, Y. Hishikawa, S. Kinugasa, and N. Nagasue, "Prognostic significance of the expressions of metallothionein, glutathione-S-transferase- π , and P-glycoprotein in curatively resected gastric cancer," *Oncology*, vol. 54, no. 5, pp. 391–399, 1997.
- [33] D. Deng, W. El-Rifai, J. Ji et al., "Hypermethylation of metallothionein-3 CpG island in gastric carcinoma," *Carcinogenesis*, vol. 24, no. 1, pp. 25–29, 2003.
- [34] Y. Pan, J. Huang, R. Xing et al., "Metallothionein 2A inhibits NF- κ B pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection," *Journal of Translational Medicine*, vol. 11, no. 1, pp. 173–186, 2013.
- [35] C. Y. Wu, Y. J. Jan, B. S. Ko et al., "Prognostic significance of 14-3-3 ϵ , aldo-keto reductase family 1 B10 and metallothionein-1 in hepatocellular carcinoma," *Anticancer Research*, vol. 38, no. 12, pp. 6855–6863, 2018.
- [36] N. A. Rezk, H. E. Zidan, M. Riad, W. Mansy, and S. A. Mohamad, "Metallothionein 2A expression and its relation to different clinical stages and grades of breast cancer in Egyptian patients," *Gene*, vol. 571, no. 1, pp. 17–22, 2015.
- [37] R. Mehrian-Shai, M. Yalon, A. J. Simon et al., "High metallothionein predicts poor survival in glioblastoma multiforme," *BMC Medical Genomics*, vol. 8, no. 68, pp. 6–15, 2015.
- [38] M. T. Brazão-Silva, M. F. Rodrigues, A. L. Eisenberg et al., "Metallothionein gene expression is altered in oral cancer and may predict metastasis and patient outcomes," *Histopathology*, vol. 67, no. 3, pp. 358–367, 2015.
- [39] S. Krizkova, M. Kepinska, G. Emri et al., "An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena," *Pharmacology & Therapeutics*, vol. 183, pp. 90–117, 2018.
- [40] X. Sun, X. Niu, R. Chen et al., "Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis," *Hepatology*, vol. 64, no. 2, pp. 488–500, 2016.

- [41] Y. Nobeyama and H. Nakagawa, "Silencing of metallothionein 1A gene in melanoma," *Journal of Dermatological Science*, vol. 88, no. 2, pp. 232–237, 2017.
- [42] J. Fu, H. Lv, H. Guan et al., "Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway," *BMC Cancer*, vol. 13, no. 1, pp. 462–475, 2013.
- [43] X. Ji, Y. C. Fan, S. Gao et al., "MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma," *World Journal of Gastroenterology*, vol. 20, no. 16, pp. 4723–4729, 2014.
- [44] C. R. Souza, M. C. Almeida, A. S. Khayat et al., " Association between *Helicobacter pylori* , Epstein-Barr virus, human papillomavirus and gastric adenocarcinomas ," *World Journal of Gastroenterology*, vol. 24, no. 43, pp. 4928–4938, 2018.
- [45] D. Salyakina and N. F. Tsinoremas, "Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data," *Human Genomics*, vol. 7, no. 1, pp. 23–30, 2013.
- [46] K. Takada, "Epstein-Barr virus and gastric carcinoma," *Molecular Pathology*, vol. 53, no. 5, pp. 255–261, 2000.
- [47] Q. Huang, C. Fang, J. Shi et al., "Differences in clinicopathology of early gastric carcinoma between proximal and distal location in 438 chinese patients," *Scientific Reports*, vol. 5, no. 1, article 13439, 2015.
- [48] N. Amini, G. Spolverato, Y. Kim et al., "Clinicopathological features and prognosis of gastric cardia adenocarcinoma: A multi-institutional U.S. study," *Journal of Surgical Oncology*, vol. 111, no. 3, pp. 285–292, 2015.
- [49] S. J. Crane, G. Richard Locke, W. S. Harmsen et al., "The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site," *Alimentary Pharmacology & Therapeutics*, vol. 25, no. 4, pp. 447–453, 2007.